18th Dec 2015 07:00
Premaitha Health plc
Director's Shareholding & Issue of Options
Manchester, UK - 18 December 2015: Premaitha Health plc ("Premaitha" or "the Company"; AIM: NIPT) has been informed that, on 17 December 2015, Barry Hextall, a director of the Company, transferred 150,000 ordinary shares to his SIPP. On the same date, Mr Hextall purchased an additional 180,736 ordinary shares at an average price of 18.03 pence per share. Following this purchase, Barry Hextall's shareholding is 332,498 ordinary shares, representing 0.15 per cent. of the Company's issued share capital.
The Company has today issued 250,000 options over ordinary shares under the Company's EMI share option scheme to an employee. The options are exercisable at any time up to 17 December 2025 at a price of 20 pence per share. Following the issue of these options, the Company has 36,238,332 shares under option and a further 23,147,658 shares under warrant.
The issued share capital of the Company comprises 228,163,709 Ordinary Shares of 10p each.
For more information, please contact: |
|
|
|
Premaitha Health plcDr Stephen Little, Chief Executive Officer Jo Cross, Head of Marketing | Tel: +44 (0) 161 667 6865Email: [email protected] Email: [email protected]
|
Cairn Financial Advisers LLP (NOMAD)Liam Murray / Avi Robinson
| Tel: +44 (0) 20 7148 7900 |
Panmure Gordon (UK) Limited (Broker)Robert Naylor / Freddy Crossley /Maisie Rose Atkinson
| Tel: +44 (0) 20 7886 2500 |
Instinctif Partners (Media)Melanie Toyne Sewell / Jen Lewis /Emma Barlow | Tel: +44 (0) 207 457 2020 Email: [email protected] |
About Premaitha Health
Premaitha is an innovative molecular diagnostics company employing the latest advances in DNA analysis technology to develop tests for non-invasive prenatal screening (NIPT) and other applications. Premaitha's flagship product, the IONA® test is the first non-invasive in vitro diagnostic product for prenatal screening enabling clinical laboratories to offer CE-marked NIPT in-house for the first time.
The IONA® test estimates the risk of a fetus having Down's syndrome or other serious genetic diseases. The IONA® test has a higher detection rate and lower false positive rate than existing screening tests, giving pregnant women, their families and their doctors greater confidence in the result and reducing the need for unnecessary invasive follow-up tests and the associated anxiety and stress. The IONA® test is a complete diagnostic system that is simple and standardised, enabling Premaitha's clinical laboratory customers to perform the test in their own facilities. This supports Premaitha's strategy of accelerating the broad dissemination of NIPT tests to ensure that their benefits are available to pregnant women everywhere.
Premaitha is listed on the London Stock Exchange (AIM). Its R&D, manufacturing and commercial operation is located at Manchester Science Park, UK. For further information please visit www.premaitha.com or email [email protected].
Related Shares:
YGEN.L